Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This WeekThe Motley Fool • 10/15/21
Beam Therapeutics: This Technology Should Be Part Of Every Investor's PortfolioSeeking Alpha • 10/01/21
Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual MeetingGlobeNewsWire • 10/01/21
Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/28/21
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV InfectionBenzinga • 09/27/21
Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B InfectionGlobeNewsWire • 09/27/21
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal StudiesBenzinga • 09/23/21
Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other TissuesGlobeNewsWire • 09/23/21
Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?The Motley Fool • 09/12/21
Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare ConferenceGlobeNewsWire • 09/08/21
Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/10/21
Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/04/21
Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/03/21